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In this review we overview the mechanisms responsible for uterine
contractility and relaxation. We then use this as the basis for discussing
the two major uterotonins, oxytocin and prostaglandins followed by
currently available (although often unlicensed) tocolytics; progesterone,
magnesium, calcium channel blockers, oxytocin receptor blockers,
b-adrenergic receptor agonists, prostaglandin synthesis inhibitors and
nitric oxide donors. In this brief review we have concentrated on the
most important mechanisms of action and data obtained on human
tissue. By focussing on mechanisms, meta-analyses and Cochrane litera-
ture reviews, our aim is to provide insight for clinical usefulness, and
highlight where further research is required and where the targets may be.
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Introduction
Pregnancy and parturition are natural events but, as with most
bodily functions, things can go wrong and nature requires
a helping hand. Along with surgical intervention, drugs are the
main mechanism used to help control the pregnant uterus. They
are used to stimulate the uterus (uterotonins) in three main
clinical scenarios: (1) to initiate uterine activity for induction of
labour or termination, (2) to augment slowly progressing labours
and (3) to stimulate delivery of the placenta and prevent post-
partum haemorrhage. They are used to relax the uterus (toco-
lytics) in cases of threatened or frank preterm labour, to prevent
or delay preterm delivery. Due to its frequency and serious
adverse effects on neonatal mortality and morbidity, it is preterm
labour that is most intensely investigated and for which most
new obstetrical drugs are trialled, and which therefore we have
spent longer reviewing. An understanding of the mechanisms of
action of tocolytics and uterotonins, is therefore essential to aid
the management of difficult pregnancies and prevent theirSarah Arrowsmith BSc MRes is a PhD Student in the Physiological
Laboratory at University of Liverpool, Liverpool, UK. Conflicts of
interest: none declared.
Annabelle Kendrick BSc MBChB is a Specialist Registrar at Liverpool
Women’s Foundation Trust Hospital, Liverpool, UK. Conflicts of interest:
none declared.
Susan Wray BSc PhD is a Professor at Liverpool Women’s Foundation
Trust Hospital, Liverpool, UK. Conflicts of interest: none declared.
OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 20:8 241associated morbidities. Both classes of drugs target the pathways
that initiate and produce uterine contractions. We therefore start
with an overview of the basics of these events.
Uterine excitability and contractility
Phasic contractions of the uterus occur due to spontaneous
changes in electrical activity within myometrial cells, the mech-
anism of which is unknown, but which leads to action potentials
and depolarization. The depolarization causes opening of
voltage-gated, L-type calcium channels, rapid calcium entry and
an elevation in intracellular [Ca] ([Ca]i) which is pivotal for
myometrial contraction. The Ca binds to calmodulin which
activates myosin light chain kinase (MLCK), leading to phos-
phorylation of the myosin regulatory light chains and, enables
the interaction of myosin with actin, cross-bridge cycling and
force development. Myosin is dephosphorylated by myosin
phosphatase (MLCP) and Ca is extruded by Ca-ATPase and Na/
Ca exchange. The membrane potential is restored to resting
levels by potassium (K) efflux and the myometrium is quiescent
until spontaneous depolarization initiates the next contraction
(see Figure 1, black arrows). Calcium entry and efflux are the
major pathways of myometrial contraction/relaxation. Agonists
by binding to their receptors on the myocyte membrane augment
or inhibit this pathway, for example by promoting depolarization
or by reducing Ca entry. However, agonists can also initiate other
intracellular pathways and signals that can influence force. These
primarily involve Ca uptake or release from the intracellular Ca
store, the sarcoplasmic reticulum (SR) or modulation of MLCK/
MLCP activity to change myosin and actin interaction (Ca
sensitization). Control of these pathways is complex and
incompletely understood, especially under physiological condi-
tions; for example, second messengers have several sites of
action and their effects may be antagonistic e.g. if PKC phos-
phorylates MLCK its activity is decreased and force falls, but
when it phosphorylates MLCP, it decreases its activity hence
prompting force.
In summary it is perhaps not surprising that the drugs (both
clinical and laboratory) we have to modulate uterine force, act to
alter the excitationecontraction that generates the phasic
contractions of the uterus, and onto which agonists exert their
effects.
The uterotoninsOxytocinWhat is it: oxytocin is a nona-peptide hormone released in
pulses from the posterior pituitary and is the basis of Syntocin
and Syntocinon.
What does it do: it has a number of roles including stimulating
contraction of myometrium and myo-epithelium of the
mammary ducts, and influencing maternal behaviour.
How does it act: activation of oxytocin receptors (OTR), in
common with many other agonists, causes the activation of
phospholipase-C b (PLCb), which hydrolyses phosphatidylino-
sitol bisphosphate (PIP2) leading to the formation of two second
messengers: IP3 and diacylglycerol (DAG). Both messengers are
thought to be involved in mediating the many cellular responses 2010 Elsevier Ltd. Open access under CC BY license.
Schematic to show the major mechanisms of action by the different uterotonins and tocolytics used to modulate
myometrial contractions
Note, each drug can have multiple sites of activity; e.g. changes in cell membrane potential and excitability, changes in levels of intracellular calcium, 
the phosphorylation state of the contractile machinery and altered myometrial gene expression.
Red arrows and bars show pathways that when activated lead to stimulation of contraction whilst blue arrows and bars show those  pathways leading to
suppression of contraction.
Figure 1
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REVIEWto oxytocin. IP3 stimulates calcium release from the SR, whilst
DAG, the main activator of Protein Kinase C (PKC) may or may
not affect myometrial tension. Using a variety of experimental
approaches, we and others have shown that stimulation of Ca
entry is the most prominent effect of oxytocin. Oxytocin also
inhibits Ca efflux mechanisms. Oxytocin may also inhibit MLCP,
slowing relaxation and enhancing force. Thus via a variety of
mechanisms oxytocin has powerful stimulatory effects which
have long been used clinically to aid parturition. During preg-
nancy, OTRs increase in number which is thought in part to
underlie the increased sensitivity of the myometrium to oxytocin
at term when little change in oxytocin levels can be detected.
Antagonists to OTR have been developed as tocolytics and are
discussed later.Clinical usesThe first clinical use of oxytocin was by Blair Bell in 1909, to stop
post-partum haemorrhage. Oxytocin is now used widely in its
synthetic forms, for labour augmentation and induction. Synto-
cin/Syntocinon is also administered during CS to cause a large
contraction for stemming bleeding. Clinically, continuous iv
infusion of oxytocin may not be optimal, as it does not replicate
its natural pulsatile release and may also cause receptor desen-
sitization and down regulation of OTR mRNA. Indeed, responses
to administration of oxytocin are variable, and a pulsatile
application of oxytocin has been shown to be more efficient than
constant oxytocin infusion to induce labour. Even so it remains
perplexing why up to 50% of women labouring poorly, do not
respond to oxytocin administration and ultimately require CS,
although difference in background acidity and lactate have
recently been suggested. Thus dysfunctional labour remains
a major contributor to the non-elective CS rate and oxytocin has
not reduced this rate. More work is required to understand the
causes of dysfunctional labour, so that they can either be pre-
vented or remedied by additional agents.
Administration of oxytocin is not without risk; uterine
hyperstimulation or rupture and foetal distress, The foetal
distress arises as the over-contracted myometrium occludes
blood vessels and diminishes placental perfusion. Thus the
effects of administration of oxytocin in cases of poor/slow
progress in the first stage of labour should always be carefully
monitored and maximal doses, which are usually higher in pri-
migravidae, not exceeded. In order to achieve successful labour
induction with oxytocin, the cervix must be favourable.ProstaglandinsWhat are they: prostaglandins (PGs) are bioactive lipids derived
from arachidonic acid. They are synthesized within the human
foetal membranes (amnion and chorion) and decidua.
What do they do: they play a major role in both the initiation
and maintenance of labour at term and also in some preterm
labours, by enhancing contractions and “ripening” the cervix.
How do they act: they act as signalling messengers for many
biochemical pathways. Their availability within the different
tissues depends upon the activity of the different enzymes that
converts their common precursor, arachidonic acid, into the
various end products. PGs act in a paracrine or autocrineOBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 20:8 243manner, mediating their functions by binding to different
G protein coupled receptors (GPCRs). Each PG has its own
specific receptor or receptors thus promoting the activation of
different intracellular signalling cascades and gene transcription.
When FP, EP1, EP3 and TP receptors are activated a contractile
response occurs, whilst EP2, EP4, IP and DP receptors initiate
relaxatory effects. In the myometrium, the two major stimulating
PGs are PGF2a and PGE. The levels of these two PGs are reported
to increase in a time-dependent manner during later gestations
indicating that they are important in the labour process. Both
influence myometrial contractility but their effects vary (see
Figure 1).PGF2a
PGF2a exerts its uterotonic effect by increasing [Ca]i allowing for
greater actinemyosin interaction and contraction, via (i) IP3-
mediated SR calcium release, (ii) increasing Ca entry as
a consequence of increasing the frequency of action potentials,
and (iii) activation of non-specific cation channels, facilitating Ca
entry. In human myometrium PGF2a may also increase the
sensitivity of the contractile apparatus to calcium. Thus as with
oxytocin, multiple targets are activated by PGF2a which syner-
gizes to promote force production.PGEThere is controversy whether PGs of the ‘E’ variety aid myometrial
contraction or relaxation. There are four isoforms of the PGE
receptor (EP1e4), which act through different intracellular path-
ways: EP1 receptors couple to calcium mobilization and thus are
uterotonins, EP3 receptors inhibit adenylyl cyclase and thus cAMP
and Protein Kinase A. As both PKA and cAMP mostly relax the
myometrium through a variety of mechanisms including
decreasing Ca channel opening, phosphorylation of MLCK and
stimulationofMLCP,EP3will thereforebe stimulatory. Conversely,
EP2 and EP4 stimulate cAMP thereby mediating relaxation.Clinical usesClinically PGs have been used for many years for termination,
and labour induction and for cervical preparation prior to the
induction of labour. As natural PGs are rapidly metabolized, but
labour induction requires their prolonged presence, PG
analogues have been developed, e.g. Misoprostol and Geme-
prost; synthetic analogues of PGE, which are used for medical
termination. PGs are more efficacious for early terminations than
oxytocin, as OTRs are not well expressed until the third
trimester. The synthetic analogue of PGF2a, Carboprost (trade-
name Hemabate), has been used for stimulating labour
contractions and reducing post-partum haemorrhage. Misopros-
tol has been successfully used for cervical ripening, but has also
shown to increase the risk of uterine hyperstimulation and is
therefore not always the preferred agent for labour induction.
Despite a greater cost, Dinoprostone (also known as Cervidil,
Prepidil or Prostin E2) is frequently used for cervical ripening
owing to its greater safety.
TocolyticsIntroductionPreterm labour, which remains a considerable obstetrical chal-
lenge, once initiated is considered to progress by the same 2010 Elsevier Ltd. Open access under CC BY license.
REVIEWmechanisms occurring in term labour but it is triggered is too
early. The trigger may be physiological, for example as occurs in
multiple pregnancy, or pathological for example due to infection.
The inhibition of uterine contractions is the basis of drugs used in
tocolysis. That there is no consensus about which agent is the
best tocolytic, and that the rate of preterm delivery has not
declined, tells the story of frustration and dashed expectations.
Long-term (>1 week) tocolysis is rarely achieved, but the task of
maintaining the pregnancy for an additional 48 h, can be
successful, allowing corticosteroid administration and if neces-
sary, transfer to a specialist centre.ProgesteroneWhat is it: progesterone, (P4; pregn-4-ene-3,20-dione) is
a steroid hormone. During pregnancy the main source of
progesterone is placental tissues.
What does it do: progesterone is a ‘pro-gestational’ agent which
maintains the pregnant state and promotes quiescence. Proges-
terone is effective in inhibiting contractions at all gestations. In
other mammals, progesterone withdrawal initiates labour but no
change occurs in serum levels in women, rather a process
described as ‘functional progesterone withdrawal’ brought about
by changes in receptor isoforms and reducing myometrial
sensitivity to progesterone, is postulated.
How does it act: the primary action of progesterone is thought to
be mediated by its interaction with the intracellular nuclear
progesterone receptor however, more recently actions via
a plasma membrane receptor (mPR) have been uncovered. It
may also have anti-inflammatory actions which aids its tocolytic
actions. Through its binding to nuclear receptors, progesterone
alters gene expression bringing about long-term changes in the
contractile phenotype of the myometrium. Progesterone inhibits
phosphodiesterase PDE4, the enzyme responsible for cAMP
inactivation, thereby increasing [cAMP]. Direct, rapid tocolytic
effects of progesterone are associated with mPRs that couple to
intracellular signalling pathways, although its exact mechanism
of action is unclear. Progesterone in vitro inhibits spontaneous
and oxytocin-induced contractions and uncouples the excita-
tionecontraction process by directly modulating [Ca]i e.g. by
inhibiting Ca entry and SR calcium release, as well as causing
membrane hyperpolarization through activation of K channels.
Progesterone may also inhibit oxytocin binding to its receptor.
However, there are also reports of progesterone stimulating Ca
entry and thus having some pre-contractile effects, at least
acutely, and effects on K channels were not found in a recent
study of human myometrium.Clinical usesProgesterone is used to prevent preterm delivery. Supplementa-
tion with progesterone or the synthetic progestin, 17a-hydrox-
yprogesterone caproate (17OHPC) has been shown to be effective
in preventing preterm labour in singleton deliveries but not
multiple pregnancies. That said, there is little evidence of long-
term benefit and The RCOG Preterm Birth study group has stated
that progesterone use should be restricted to randomized
controlled trials (see Management of Preterm Labour in this
issue, pp 235e240).OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 20:8 244When the effects of progesterone and its analogue were tested
in vitro on myometrial strips, only progesterone and not 17OHPC
was effective in reducing myometrial contractility, which is
difficult to explain on our current understanding. Antiprogestins
including Mifepristone (RU 486) have been developed to antag-
onize the action of progesterone and have clinical use for
induction of labour or medical termination of pregnancy in early
or mid trimester. Studies in mice have shown that Mifepristone
can induce labour in late pregnancy whilst oral Mifepristone
administration to women increased uterine activity.MagnesiumWhat is it: a co-factor for many reactions and an antagonist to
Ca.
What does it do: it competes with Ca and thereby affects
multiple intracellular pathways. It has long been used in
obstetrics as a tocolytic and more recently to prevent and treat
eclamptic convulsions.
How does it act: magnesium acts to relax smooth muscle and
hence its administration is associated with vasorelaxation and
tocolysis. Surprisingly, although MgSO4 was identified as a toco-
lytic over 40 years ago and is often the first line tocolytic in the
USA, there is still uncertainty about the underlying mechanism. It
acts extra- and intracellularly and decreases Ca entry and
possibly SR Ca release. Physiologically there is an antagonism
between Mg and Ca which reducing L-type Ca channel entry, one
of its main actions. Magnesium induces a dose dependent
decrease in [Ca]i and force in spontaneously and oxytocin-
induced contracting pregnant human myometrium. Magnesium
may decrease the generation of phospholipase-C and hence IP3
generation and stimulate translocation of PKC from cytosol to the
cell membrane.Clinical usesThere is little evidence supporting MgSO4 efficacy in preventing
preterm labour and delivery. Thus the 2009 Cochrane review
concluded “Magnesium sulphate is ineffective at delaying birth
or preventing preterm birth”, and of its use as a maintenance
tocolytic concluded; “There is not enough evidence to show any
difference between magnesium maintenance therapy and either
placebo or no treatment”. This review follows several earlier
studies reporting either no benefit or no difference from other
tocolytics and even possible harm, although these conclusions
are not supported by all. More recently, evidence has been pre-
sented suggesting that magnesium provides neuro-protection to
the premature infant, possibly due to vasodilation and increased
placental perfusion as well as NMDA antagonism. Finally, there
appears to be little or no data demonstrating a prolongation of
normal labour but an increase in CS rate. Magnesium deficiency
may also contribute to pre-eclampsia and along with aspirin and
Ca has been suggested as a supplement to prevent pre-eclampsia
in high risk women.Calcium channel blockersWhat are they: drugs such as nifedipine developed to block
voltage-gated Ca channels were originally introduced to treat
hypertension. 2010 Elsevier Ltd. Open access under CC BY license.
REVIEWWhat do they do: prevent the normal rise of [Ca]i produced by
stimulation and depolarization.
How do they act: blocking of calcium channels prevents the
entry of Ca and the spread of the action potential, required for the
myometrium to contract in a coordinated manner. In vitro
nifedipine and other calcium channel blockers such as Diltiazem,
reduce and then abolish the contractility of myometrium from
preterm and term women, and this is associated with the aboli-
tion of Ca transients. The reduction in contractility has been
reported to be less pronounced in samples from labouring
women. Electrophysiological experiments on freshly isolated
myocytes show nifedipine abolishes inward current. The uterus
also expresses a small number of T-type Ca currents. Mibefradil,
a blocker of T-type channels has been reported to cause
a significant reduction in the contractility of pregnant human
myometrium, but as a reduction was also found in calcium free
medium, it is suggested to also inhibit calcium release from the
SR.Clinical useCompared to other tocolytic agents, calcium channel blockers
significantly delay birth (7 days) when used before 34 weeks.
Most of these trials involved the comparison of nifedipine with
ritodrine, a beta adrenergic agent, discussed later. However, no
placebo-control trials have addressed the acute management of
preterm labour, and there is uncertainty about the optimal form,
dose and route of administration for calcium channel blockers
(see Management of Preterm Labour in this issue, pp 235e240).
Nifedipine is associated with a reduction in the rate of respiratory
distress syndrome, not just by allowing time for the use of
corticosteroids but by a direct action on neonatal pulmonary
perfusion. The side effect profile of calcium channel blockers has
been heralded as superior to beta adrenergic agonists with fewer
women stopping this treatment due to adverse effects and
a reduction in neonatal side-effects such as respiratory distress
syndrome, intraventricular haemorrhage and necrotizing
enterocolitis. However, perhaps not surprisingly given its known
use as an antihypertensive drug, cases of maternal hypotension
and concerns about placental perfusion have been raised. It has
been suggested that as calcium channel blockers are not licensed
for tocolysis, under reporting of adverse events may hide the
scale of this problem and caution is recommended, particularly
in women with cardiovascular morbidity.Oxytocin antagonists as tocolyticsWhat are they: drugs which act as antagonists to the oxytocin
receptor.
What do they do: they bind to OTR preventing the effects of
oxytocin.
How do they act: the patho-physiology of preterm labour is still
not understood however women with preterm labour were
shown to have a higher sensitivity to oxytocin and a higher OTR
concentration compared to women of a similar gestational age
but not in labour. By preventing oxytocin binding this stimula-
tion of uterine contractions should be inhibited. Atosiban, an
oxytocin derivative is a competitive inhibitor of OTR as well as
the vasopressin (V1a) receptor. In vitro, Atosiban was shown toOBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 20:8 245abolish the uterotonic activity of oxytocin in human and animal
myometrium and shown in parturient rats to down-regulate
OXTRs. Barusiban, has a higher affinity for the OTR and higher
potency than Atosiban, and is without side-effects of vasopressin
receptor antagonism. In vitro it has been shown to inhibit
contraction of human myometrium at least as potently as
Atosiban.Clinical useAtosiban was shown to achieve significant prolongation of
gestation in a placebo-controlled trial. In the 2005 Cochrane
intervention review of OTR antagonists for inhibiting preterm
labour, Atosiban was superior neither to b2-AR agonists or
placebo in both tocolysis and neonatal outcome. Furthermore,
increased infant death was found. In a recent randomized
controlled trial examining the effect of Barusiban on delivery and
uterine contractility in women with threatened preterm labour at
late gestational age, Barusiban was shown to be ineffective in
delaying delivery or reducing uterine contractions. Thus it would
seem that the early hope for anti-oxytocics has not been fulfilled.b-adrenergic receptor agonistsWhat are they: drugs developed to stimulate b2-adrenergic
receptor (b2-AR), such as Terbutaline, Ritodrine, Salbutamol.
What do they do: relax smooth muscle including the
myometrium.
How do they act: as agonists at b2-AR they activate adenylyl
cyclase, thereby increasing cAMP and activating PKA. There are
three subtypes of b-AR in the myometrium but b2-AR is the
predominant (80%) form, although changes in receptor expres-
sion towards term and differences between women may occur. It
has been postulated that a reduction or down regulation of b2-AR
may have a role in the onset of preterm labour, although whether
b2-AR decreases preceded the onset of labour or occurred as
a consequence of labour is unclear. In rat myometrium proges-
terone but not oestradiol is associated with increased b2-AR
transcription and elevation of b2-AR density. Moreover, proges-
terone has been shown to enhance the relaxant effect of ritodrine
in gravid human myometrial samples, however, this may be due
to direct inhibition of OTR and not the action of progesterone on
the b2-AR, and has not been found by others. As well as the long-
established ability of b2-AR agonists to relax the uterus, more
recently several b3-AR agonists have been reported to reduce
contractility of isolated myometrial strips in a dose dependent
manner mediated via cAMP. Studies suggest that this effect is
also mediated through an increase in cAMP. A study using
implanted intrauterine telemetric sensors into pregnant monkeys
demonstrated the in vivo tocolytic effect of a b3 agonist
(SAR150640) and reduced side-effects compared to ritodrine. The
b3-ARs also appear not to desensitize, a major drawback to b2-AR
therapy. Further work is required to elucidate the role of b3 in the
treatment of preterm labour.Clinical useThere is a large body of evidence supporting the use of b2-
adrenergic receptor (b2-AR) agonists for the treatment of preterm
labour, as they decrease the number of women delivering within
48 h. The extent of the tocolysis produced by b2 agonists is 2010 Elsevier Ltd. Open access under CC BY license.
REVIEWhowever limited. The widespread distribution of b2-AR results in
an extensive sided effects profile, including palpitations, chest
pain, shortness of breath, nausea, and in extreme cases pulmo-
nary oedema and even maternal death, result in discontinuation
of therapy. Desensitization also occurs and b2 agonists are not
effective for maintenance therapy after preterm delivery has been
abated. Unfortunately the delay in delivery produced by b2-AR
agonists has not translated into an improvement in foetal
outcome, although it must be noted that the use of corticoste-
roids for lung maturation was not routine when many of the
trials were conducted. Terbutaline is also widely used clinically
for hyperstimulation during labour. As b2-AR agonists occupy the
receptor for a considerable length of time, they are irreversible in
the short term, unless a b-blocking drug is given. Thus there is
a risk of post-partum haemorrhage following b2-AR agonist
tocolysis, as oxytocin is ineffective.Prostaglandin synthesis inhibitorsWhat are they: drugs that prevent the synthesis of prostaglan-
dins. They include inhibitors of prostaglandin endoperoxide H
synthase (PGHS), also known as cyclooxygenase (COX), familiar
as non-steroidal antiflammatory drugs (NSAID) such as
Indomethacin.
What do they do: decrease myometrial prostaglandin output.
How do they act: they inhibit the enzymes and pathways of
prostaglandin production and thereby reduce myometrial
contractions. There are two COX isoforms, COX1 and COX2
which bring about the conversion of arachidonic acid to PGH2
and hence the many different and tissue specific PGs. The COX1
enzyme is considered to be constitutively active and COX2
induced. The NSAIDs inhibit COX1 and COX2 and were first used
as tocolytics, followed by the development of selective inhibitors
for both COX1 and COX2, e.g. SC58560 (COX1) and celecoxib
and meloxicam (COX2). In vitro data have demonstrated the
inhibition of uterine contractions with NSAIDs, but not inhibition
of PG, and a primary effect of these drugs on Ca channels has
been postulated. In their study carefully examining a range of
COX1 and COX2 inhibitors, Sawdy et al concluded that, as there
was no relationship between myometrial inhibition and PG
production, myometrial contractions are not dependent on
myometrial COX activity or PG production, although in vivo local
(e.g. foetal membrane) PG production may affect the myome-
trium. Another tocolytic approach is inhibition of PG receptors;
THG113 a blocker of PGF receptors has been shown in animal
models to delay premature delivery and reduce uterine activity.Clinical useSeveral trials of COX inhibitors as tocolytics particularly indo-
methacin, have been undertaken. A meta-analysis of outcome
data from 13 trials concluded “There is insufficient information
on which to base decision about the role of COX inhibition for
women in preterm labour”. Furthermore several serious side-
effects have been reported, including necrotizing enterocolitis,
patent postnatal ductus arteriosus and oligohydramnios which
occurred when COX2 specific inhibitors were trialled. In the
TOCOX trial of Rofecoxib, a newer COX2 inhibitor, no reduction
in the incidence of preterm delivery occurred but it wasOBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 20:8 246associated with increased risk of delivery before 37 weeks in high
risk women.Nitric oxide donorsWhat are they: producers of the short lived, metabolically active
gas, NO e.g. glyceryl trinitrate.
What do they do: relax smooth muscle, particularly that of blood
vessels.
How do they act: NO increases levels of cGMP and PKG and can
thereby affect several pathways associated with relaxation. NO is
formed from of L-arginine by the action of NO synthetase. Given
its clear role in vasodilation via the endothelium it is not
surprising that in reproduction a role for it has been suggested
during implantation and menstruation and disorders of its
production associated with pre-eclampsia, IUGR, dysmenorrhoea
and infertility. There was considerable interest in NO as a toco-
lytic following firstly reports of its ability to inhibit in vitro
uterine contractions and then, that the NO donor glyceryl trini-
trate when used as a patch on the abdomen, could prevent
preterm labour. However, since these early reports, contradictory
results regarding the relaxant effects of NO appeared. One
important issue has always been that there was much earlier
evidence showing that cGMP does not relax the uterus, sug-
gesting that NO must be effecting another pathway. Buxton et al
provide evidence that this may be a K channel-mediated
mechanism.Clinical useNitric oxide donors have been employed for cervical ripening,
labour induction and tocolysis. In a 2002 intervention review,
five randomized controlled trials were identified (466 women)
and nitroglycerine was the NO donor in all five studies. The
main finding was that NO did not delay labour or improve
neonatal outcome compared to placebo or alternative tocolytic,
although it was well tolerated. In 2004 the RNOTT trial of NO
tocolysis reported that NO (GTN) is less efficacious than b2-AR
agonists.
Summary
An understanding of the mechanism of excitationecontraction in
myometrium provides a good basis for predicting tocolytic
targets. When translating this knowledge into producing thera-
peutic agents several concerns are raised which focus around
specificity and efficacy. Thus for example, it is hard to suggest
that MgSO4 or nifedipine will produce selective effects on myo-
metrium given the widespread distribution of L-type Ca channels
and the multitude of reactions including Mg. Desensitization and
side-effects are other problems encountered that limit long-term
use. Comparison of trial outcomes between existing tocolytics or
placebo can be found in sources such as Cochrane Reviews, and
often these make depressing reading in terms of proven tocolytic
efficacy e.g. for Mg, or in effectiveness of new drugs, such as
oxytocin receptor antagonists. It is worth noting that one of the
oldest tocolytics around, progesterone is currently enjoying
a renaissance, at least for singleton pregnancies. The goal of
preventing preterm births is such a worthy one that research into
both the underlying causes and devising better drugs must 2010 Elsevier Ltd. Open access under CC BY license.
Practice points
C The excitationecontraction pathway is the target for all utero-
tonic and tocolytics drugs, thus an understandingof it is helpful.
C Ultimately a rise of intracellular [Ca] determines uterine
contraction and a fall of [Ca] relaxation.
C Oxytocin and prostaglandin and their synthetic derivatives are
the most commonly used uterine stimulants. They are used to
speed up labour, stem bleeding, termination and labour
induction but have the risk of uterine hyperstimulation and
rupture.
C Once preterm labour is initiated there is a very powerful
driving force for contraction which is hard to halt and reverse.
Tocolysis beyond 48 h remains a significant challenge, but
progesterone and Ca channel blockers can be used.
C There is a lack of supporting evidence for the use of some
tocolytics and some may do harm. Thus well designed trials
and new approaches to tocolysis are required.
REVIEWcontinue. We also suggest that focus on the drugs that meta-
analysis has shown to be superior e.g. prostaglandin inhibitors
and calcium channel blockers. A
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